holoxan 40 mg/ml infusionsvätska, lösning
baxter medical ab - ifosfamid - infusionsvätska, lösning - 40 mg/ml - ifosfamid 40 mg aktiv substans - ifosfamid
holoxan pulver till injektions-/infusionsvätska, lösning
paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans
holoxan pulver till injektions-/infusionsvätska, lösning
paranova läkemedel ab - ifosfamid - pulver till injektions-/infusionsvätska, lösning - ifosfamid 1 mg aktiv substans
cyclophosphamide accord 500 mg pulver till injektions-/infusionsvätska, lösning
accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - cyklofosfamidmonohydrat 534 mg aktiv substans; mannitol hjälpämne
cyclophosphamide accord 1000 mg pulver till injektions-/infusionsvätska, lösning
accord healthcare b.v. - cyklofosfamidmonohydrat - pulver till injektions-/infusionsvätska, lösning - 1000 mg - mannitol hjälpämne; cyklofosfamidmonohydrat 1069 mg aktiv substans
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, follikel - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
tecvayli
janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiska medel - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiska medel - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.